New studies into retatrutide, a dual agonist for GLP-1 and GIP receptors, are revealing significant effects in treating obesity and diabetes non-insulin-dependent diabetes. Animal evidence suggest a novel mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/